# Atara Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atara-biotherapeutics

- Industry: Biotechnology
- Headquarters: Thousand Oaks, US
- Website: www.atarabio.com
- Total disclosed funding: $52M
- Latest round: Series B (Jan 10, 2014)
- Investors on record: 8

## About

Founded in 2012 by founder Isaac Ciechanover and based in California, US, Atara Biotherapeutics, Inc. leverages the natural biology of T cells to create allogeneic T-cell immunotherapies to harness the body's immune system to deliver cells.  In January 2024, Atara Biotherapeutics, Inc. raised USD 15 million in a private placement, selling 27.3 million shares on the Nasdaq Global Select Market. As of July 2024, the company is led by CEO Pascal Touchon. The transaction is expected to close in the first quarter of 2024, pending regulatory approvals and requirements.
 
Atara's product portfolio includes the EBV T-cell platform, which uses allogeneic T cells to target and destroy disease-causing cells. The company's tab-cel (tabelecleucel), is an investigational therapy designed to treat Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-associated cancers. In addition to tab-cel, Atara is developing several other advanced therapies, including ATA188 for multiple sclerosis and ATA3219, a CAR T therapy targeting CD19 for B-cell malignancies. CAR T cells are genetically engineered T cells designed to recognise and attack specific cancer cells.

## Funding rounds

- Series B, Jan 10, 2014, $14M — Domain Associates, Kleiner Perkins, DAG Ventures, Baupost Group, Alexandria Venture Investments, Amgen Ventures, Celgene, EcoR1 Capital
- Series B, Dec 17, 2013, $39M — Domain Associates, Kleiner Perkins, DAG Ventures, Alexandria Venture Investments, Amgen Ventures, Celgene, EcoR1 Capital

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B
- DAG Ventures (https://capitalatlas.ai/funds/dag-ventures) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- Celgene — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Baupost Group — Series B